새로운 항정신병약물의 부작용과 처치에 관한 분석의약보건레포트

새로운 항정신병약물의 부작용과 처치에 관한 분석

레포트 > 의약보건

인 쇄

바로가기저장

파일 :

새로운 항정신병약물의 부작용과 처치에 관한 분석.hwp [Size : 46 Kbyte ]

분량 9 Page

가격 1,000 원

네이버 ID로
다운 받기

카카오 ID로
다운 받기

구글 ID로
다운 받기

페이스북 ID로
다운 받기

자료설명

새로운 항정신병약물의 부작용과 처치에 관한 분석자료입니다.

up새로운항정신병약물의부작용과처치에관한분석

목차/차례

[ 목 차 ]

1. 추체외로 부작용

2. 지연성 운동장애

3. 신경이완제 악성 증후군

4. 심혈관계 부작용

5. 체중 증가

6. 강박 증상

7. 기타 부작용

1) 성기능 장애

2) 경련

3) 진정효과

4) 간독성

5) 무과립구증

5) 항콜린성 부작용
참고문헌

본문/내용

정신분열병 환자의 약물 선택과 순응도에 영향을 미칠 수 중요한 요소이다. 하지만 환자들이 이러한 부작용을 스스로 말하기는 쉽지 않기에 실제적인 빈도나 정도는 덜 알려져 있는 것으로 보인다. clozapine은 성욕을 증가시키고 월경주기를 회복시킬 뿐만 아니라 혈중 prolactin의 비정상적 증가가 없어 임신 가능성을 주의해야 한다. risperidone은 용량과 관련하여 prolactine을 비정상으로 증가시키지만 유방압통이나 유루증, 무월경은 적은 편이다55). olanzapine은 risperidone과 비교해 혈중 prolactine 증가나 사정 지연이 유의하게 적었다41). 임상가는 시작부터 환자의 성생활에 대한 자세한 정보를 얻어야 하며 환자가 성기능 장애를 호소하면 용량을 낮추든지 조언을 하여 개입을 하여야 한다.

참고문헌

참고문헌

1) Casey DE(1995) : Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. In: Schizophrenia. Ed by Hirsch S and Weinberger DR, Oxford, England, Blackwell, pp 546-565
2) Peacock L, Solgaard T, Lublin H, Gerlach J(1996): Clozapine versus typical antipsychotics: a retro- and prospective study of extrapyramidal side effects. Psychopharmacology(Berl) 124: 188-196
3) Safferman A.Z, Lieberman JA, Pollack S, Kane JM(1992): Clozapine and akathisia. Biol Psychiatry 31: 753-754
4) Chengappa KN, Shelton MD, Baker RW, Schooler NR, Baird J, Delaney J(1994) : The prevalence of akathisia in patients receiving stable doses of clozapine. J clin Psychiatry 55(4): 142-145
5) Safferman A.Z, Lieberman JA, Pollack S, Kane JM(1993): Akathisia and clozapine treatment. Schizophrenia Res 9: 248-249
6) Kastrup O, Gastpar M, Schwartz M(1994) : Acute dystonia due to clozapine(letter). J Neurology, Neurosurgery and Psychiatry 55:119
7) Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W(1993): Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J clin Psychopharmacol 73: 25-40
8) Marder SR, Meibach RC(1994) : Risperidone in the treatment of schizophrenia. Am J Psychiatry, 151:825-835
9) Simpson GM, Lindenmayer J-P(1997): Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 17: 194-201
10) Kopala LC, Kimberley PG, Honer WG(1994): Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 17: 308-313
11) Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, the olanzapine HGAD study group(1996): Olanzapine versus placebo and haloperidol: acute phase results of the North Americal double-blind olanzapine trial. Neuropsychopharmacology 14: 111-123
12) Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM(1997): Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 58: 205-211
13) Leysen JE, Janssen PMF, Schotte A, Luyten WH, Megens AA(1993): Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology(Berl) 112: S40-S54
14) Kapur S, Remington G(1996): Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466-476
15) Skarsfeldt T(1995) : Differential effects of repeated administration of novel antipsychotic drug on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281: 289-294
16) Stockton ME, Rasmussen K(1996): Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A19 and A10 dopamine neurons. Neuropsychopharmacology 14: 97-104
17) Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane JM(1991): The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158: 503-510
18) Spivak B, Mester R, Abesgaus L, Wittenberg N, Aldersberg S, Gonen N, Weizman A(1997): Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 58: 318-322
19) Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM(1994): Clozapine in tardive dyskinesia: Observation from human and animal model studies. J Clin Psychiatry 55(Suppl B): 102-106
20) Addington DE, Toews J, Addington JM(1995) : Risperidone and tardive dyskinesia: Case report. J Clin Psychiatry 56: 484-485
21) Arnand VS, Dewan MJ(1996): Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Ann Clin Psychiatry 8: 179-181
22) Buzan RD(1996): Risperidone-induced tardive dyskinesia(letter). Am J Psychiatry 153: 734-735
23)Woerner MG, Sheitman BB, Lieberman JA, Kane J(1996): Tardive dyskinesia induced by risperidone?(letter) Am J Psychiatry 1996: 843
24) Daniel DG, Smith K, Hyde T, Egan M(1996): Neuroleptic-induced tardive dyskinesia (letter). Am J Psychiatry 153: 734
25) Saran BM(1998): risperidone-induced tardive dyskinesia(letter). J Clin Psychiatry 59: 29-30
26) Gutierrez-Esteinou R, Grebb JA(1997): Risperidone: an analysis of the first three years in general use. Int Clin Psychopharmacol 12(suppl 4): S3-S10
27) Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH(1997): Blind, controlled, lon-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 154: 1248-1254
28) Keck PE Jr, Pope HG Jr, McElroy SL(1987): Frequency and presentaion of neuroleptic malignant syndrome: a prospective study. Am J Psychiatry 144: 1344-1346
29)Umbricht D, Kane JM(1996): Medical Complications of New Antipsychotic Drugs. Schizophr Bull 22: 475-481
30) Hasan S, Buckley P(1998): Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 155: 1113-1116
31) Pelonero AL, Levenson JL, Pandurangi AK(1998): Neuroleptic malignant syndrome: a review. Psychiatric Services 49: 1163-1172
32) Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT(1994): Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151: 20-26
33) Lieberman JA, Safferman AZ, Pollack S(1994): Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 151: 1744-1752
34) Young CR, Bowers MB, Mazure CM(1998): Management of the adverse effects of clozapine. Schizophr Bull 24: 381-390
35) Peuskens J(1995): Risperidone in the treatment of patients with chronic schizophrenia : A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 166: 712-733
36) Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielson M, Salvensen I(1993) : Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbation. Acta Psychiatr Scand 88: 395-402
37) van Kammen D, McEvoy J, Targum S, Kardatzki D, Sebree TB(1996): A randomized, controlled, dose-ranging trial of sertindol in patients with schizophrenia. Psychopharmacology(Berl) 124: 168-175
38) Brecher MB, Lemmens P, van Baelen B(1997): Tolerability and cardiovascular safety of risperidone. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 21, San Diego, Calif. Abstract NR 612: 233
39) Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD(1997) : Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17: 407-418
40) Safferman AZ, Lieberman JA, Kane JM, Szymanski S, Kinon B(1991): Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 17: 247-261
41) Marinkovic D, Timtijevic I, Babinski T, Totic S(1994): The side effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacology 18: 537-544
42) Stahl SM(1998): Neuropharmacology of obesity: my receptors made me eat it. J Clin Psychiatry 59: 447-448
43) Umbricht D, Pollack S, Kane JM(1994): Clozapine and weight gain. J Clin Psychiatry 55(suppl B): 157-160
44) Bustillo JR, Buchanan RW, Donna Irish, Breier A(1996): Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 153: 817-819
45) Baker RW, Chengappa KN, Baird JW, Steingard MD, Christ MA, Schooler NR(1992): Emergence of dbsessive-compulsive symptoms during treatment with clozapine. J Clin Psychiatry 53: 439-442
46) Patil VJ(1992): Development of transient obsessive-compulsive symptoms during treament with clozapine(letter). Am J Psychiatry 149: 272
47) Levkovitch Y, Kronnenberg Y, Gaoni B(1995): Can clozapine trigger OCD?(letter) J Am Child Adolescent Psychiatry 34: 263
48) Ghaemi SN, Zarate CA, Popli AP, Pilay SS, Cole JO(1995): Is there a relationship between clozapine and obsessive-compulsive disorder?: a retrospective chart review. Compr Psychiatry 36: 267-270
49) Kopala LC, Honer WG(1994): Risperidone, serotonergic mechanism, and obsessive- compulsive symptoms in schizophrenia(letter). Am J Psychiatry 151: 1714-1715
50) Remington G, Adams M(1994): Risperidone and obsessive-compulsive symptoms (letter). J Clin Psychopharmacol 14: 357-358

장바구니